Aiosyn employs deep learning models to discern between normal and abnormal tissue patterns with unprecedented accuracy, accelerating and improving clinical workflow. They provide several solutions for clinical diagnostics that reduce workflow inefficiencies by streamlining the process of pathological examination, improving its overall quality, and reducing its cost. Current products offered by Aiosyn focus on breast and prostate cancer diagnosis, and they are expanding to applications involving colorectal, lung and kidney tissue. Additionally, they have designed specific solutions for the Life Sciences industry in order to identify novel pathology-based biomarkers that can accelerate drug development. Aiosyn offers a highly interoperable platform (cloud or on-premise), with a focus on ISO-13485 certification, competitively priced, and ready to accommodate any size of workload at global scale.